Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Advances in Cardiomyopathies
share announcement

Clinical Advances in Cardiomyopathies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (25 July 2023) | Viewed by 4985

Special Issue Editors

Dr. Soumojit Pal

E-Mail Website
Guest Editor
Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Interests: cardiomyopathy; cardiomyocyte hypertrophy; heart failure; cardiac calcium signaling; hiPSC-cardiomyocyte biology; cardiomyocyte cell cycle regulation and DNA damage
Dr. Gianluca Di Bella

E-Mail Website
Guest Editor
Clinical and Experimental Department of Medicine, University of Messina, Messina, Italy
Interests: cardiomyopathies; cardiac imaging; cardiac magnetic resonance; heart failure; rare heart diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiomyopathies are diverse conditions of the heart muscle that cause mechanical and/or electrical dysfunction, resulting in hypertrophic, dilated or restrictive pathophysiology. Cardiac sarcomeric gene mutations are a common cause of cardiomyopathy development in humans, frequently leading to heart failure and sudden death. Family history with genetic testing helps to screen the carriers at birth, but symptoms are often mild or absent until late childhood or adolescence. Despite recent advances, there is still a lack of consistent early diagnostics capable of helping to detect early disease development. In this Special Issue, we would like to invite original research and review papers concerning clinical advances in cardiomyopathies. Considering your experience and expertise in this area, we hope you can offer a scientific contribution to be published in this Special Issue.

Dr. Soumojit Pal
Dr. Gianluca Di Bella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiomyopathy
  • pathophysiology
  • heart failure
  • cardiac arrhythmias
  • hypertrophy
  • echocardiography
  • diagnosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1123 KiB  
Article
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
by Michael Gotzmann, Pauline Henk, Ulrik Stervbo, Arturo Blázquez-Navarro, Andreas Mügge, Nina Babel and Timm H. Westhoff
J. Clin. Med. 2023, 12(13), 4458; https://doi.org/10.3390/jcm12134458 - 03 Jul 2023
Cited by 2 | Viewed by 1148
Abstract
Background: The inhibition of sodium-glucose co-transporter 2 (SGLT-2) has been shown to be beneficial in the treatment of diabetic and non-diabetic patients with heart failure. The underlying mechanisms are incompletely understood. The present prospective study investigates for the first time the effect of [...] Read more.
Background: The inhibition of sodium-glucose co-transporter 2 (SGLT-2) has been shown to be beneficial in the treatment of diabetic and non-diabetic patients with heart failure. The underlying mechanisms are incompletely understood. The present prospective study investigates for the first time the effect of empagliflozin on various soluble markers of inflammation in patients with reduced ejection fraction (HFrEF). Methods: We included 50 inpatients with HFrEF and diabetes mellitus type 2. A total of 25 patients received a therapy with the SGLT-2-inhibitor empagliflozin in addition to standard medication; the other 25 patients did not receive empagliflozin and were considered the control group. Quality of life, functional status and soluble immunological parameters in serum were assessed at baseline and after 3 months. Results: The baseline characteristics of both groups revealed no significant differences. Patients on empagliflozin demonstrated a significant improvement in the Minnesota living with heart failure questionnaire (baseline 44.2 ± 20.2 vs. 24 ± 17.7; p < 0.001), in distance in the 6-min walk test (baseline 343 ± 145 m vs. 450 ± 115 m; p < 0.001) and in soluble interleukin-6 level (baseline 21.7 ± 21.8 pg/mL vs. 13.7 ± 15.8 pg/mL; p = 0.008). There was no significant change of these or other parameters in the control group (p > 0.05 each). Conclusions: The empagliflozin-induced improvement of quality of life and functional capacity in patients with HFrEF and type 2 diabetes mellitus is accompanied by a substantial reduction of interleukin-6 levels. Thus, anti-inflammatory effects may contribute to the benefits of SGLT-2-inhibitors in heart failure. Full article
(This article belongs to the Special Issue Clinical Advances in Cardiomyopathies)
►▼ Show Figures

Figure 1

12 pages, 635 KiB  
Article
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by Andrea Di Lenarda, Gabriele Di Gesaro, Filippo Maria Sarullo, Daniela Miani, Mauro Driussi, Michele Correale, Claudio Bilato, Andrea Passantino, Erberto Carluccio, Alessandra Villani, Luca degli Esposti, Chiara d’Agostino, Elena Peruzzi, Simone Poli and Massimo Iacoviello
J. Clin. Med. 2023, 12(2), 699; https://doi.org/10.3390/jcm12020699 - 16 Jan 2023
Cited by 5 | Viewed by 3308
Abstract
Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced ejection fraction (HFrEF). However, data of its routine real-world use are limited, and evidence from Italian settings is lacking. The REAL.IT study [...] Read more.
Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced ejection fraction (HFrEF). However, data of its routine real-world use are limited, and evidence from Italian settings is lacking. The REAL.IT study aimed to characterize the demographics, pharmacotherapy, clinical characteristics and outcomes of sacubitril/valsartan-treated Italian patients with HFrEF. Electronic medical records of patients initiating sacubitril/valsartan from October 2016 to June 2019 at nine specialized hospital outpatient HF centers across Italy were reviewed. Overall, 924 adults (mean age 64.5 years, 84.6% male) were included. At baseline, 38.7% had an ischemic HF etiology, 45.9% hypertension, 23.2% atrial fibrillation, 25.4% diabetes mellitus, 26.1% an implantable cardioverter-defibrillator and 31.9% coronary artery bypass grafting. There were no clear patterns of patient selection over time. During follow-up, NYHA class improved in 37.5% of patients after a mean of 5.3 ± 3.8 months; 36.1% and 16.7% of patients were in NYHA class III during characterization and after one year of follow-up, respectively. Left ventricular ejection fraction (LVEF) improved ≥5% in 56.3% of patients at one year; 39.7% had ≥30% reduction of N-terminal pro-B-type natriuretic peptide; 2.2% had hyperkalemia during characterization and 2.6% during follow-up; and 3.8% had hypotension during characterization and 12% during follow-up. A total of 50 (5.8%) of patients had device implantation (ICD/CRT) during follow-up. HF-related hospitalization was recorded in 19.6% of patients during follow-up; 3.8% of patients died, approximately 1.3% from cardiovascular causes. Our real-world data confirm the favorable effectiveness and tolerability of sacubitril/valsartan observed in pivotal randomized controlled trials. Full article
(This article belongs to the Special Issue Clinical Advances in Cardiomyopathies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop